Viral load as a surrogate end point in HIV disease

Annals of Pharmacotherapy

Volumn 36, Issue 2, 2002, Pages 280-287

  Smith, Curtis L ^a   Stein, Gary E ^b  

^a FERRIS STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Human immunodeficiency virus; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CAUSE OF DEATH; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; MONITORING; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; TIME; TREATMENT OUTCOME; VALIDATION PROCESS; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HIV INFECTIONS; HUMANS; MEDLINE; QUALITY OF LIFE; THERAPEUTIC EQUIVALENCY; VIRAL LOAD;

EID: 0036165831     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A118     Document Type: Article

References (36)

1. Surrogate markers in HIV disease
2. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine
3. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1
4. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
5. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: Total lymphocyte count fluctuations and diurnal cycle are important
6. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: A review
7. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: Which to choose and how to use
8. A rapid and simple PCR assay for quantitation of HIV-1 RNA in plasma: Application to acute retroviral infection
9. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay
10. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: Enhanced sensitivity
11. Use of HIV viral load in clinical practice: Back to the future
12. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
13. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: Markers with reciprocal predictive value over time after seroconversion
14. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men
15. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
16. Course of viral load throughout HIV-1 infection
17. Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4+ lymphocytes
18. AIDS onset at high CD4+ cell levels is associated with high HIV load
19. Longitudinal analysis of CD4 T cell counts, T cell reactivity, and human immunodeficiency virus type 1 RNA levels in persons remaining AIDS-free despite CD4 cell counts <200 for >5 years
20. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study
21. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children
22. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users
23. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men
24. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy
25. Association of plasma human immunodeficiency virus type 1 RNA levels with risk of clinical progression in patients with advanced infection
26. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response
27. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
28. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
29. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
30. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
31. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen
32. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis
33. Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients
34. Health-related quality of life and virologic outcomes in an HIV clinic
35. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection